SEC Form SC 13G filed by Bionano Genomics Inc.
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 9/10/2024 | Buy → Neutral | BTIG Research | |
| 1/5/2023 | $4.00 | Sector Outperform | Scotiabank |
| 12/12/2022 | $3.50 | Buy | BTIG Research |
| 7/18/2022 | $12.00 | Outperform | Oppenheimer |
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party pay
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit. We are pleased to see consistent utilization of our OGM systems and software combined with a year-over-year growth in consumables purchased by our customers we consider to be routine users of OGM. After significant reductions in costs and cash burn, together with our gross margin improve
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs)In 15% or 75 of 519 cases, OGM identified additional Tier 1 variants with detection rates varying by disease type, ranging from 52% in T-ALL to 0% in MPN. Every Tier 1 SV or CNV detected by OGM had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection would provide additional clinical utility SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASD
Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral
BTIG Research downgraded Bionano Genomics from Buy to Neutral
Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
10-Q - Bionano Genomics, Inc. (0001411690) (Filer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 31st, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/5v2s5x5r Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)